Researchers is substantially boosted the course of a novel therapy for amyloid heart disease, leveraging Attruby. Preliminary trial results suggests significant outcomes for individuals diagnosed with a severe disease. The effort highlights BridgeBio's dedication to managing unmet medical needs i